Bluebird's not looking to break speed records with its first gene therapy launch

10th May 2019 Uncategorised 0

Bluebird CEO Nick Leschly showed analysts a picture of a roller coaster Thursday as he discussed the imminent rollout of the company’s first product, the gene therapy Zynteglo. The takeaway? Don’t expect a quick ramp-up for its initial launch.

More: Bluebird's not looking to break speed records with its first gene therapy launch
Source: fierce